Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus Johnsonii N6.2 Supplementation in Adults With Type 1 Diabetes
NCT03961347Phase 2Completed
- Sponsor
- University of Florida
- Start
- Feb 2020
- Primary completion
- Mar 2026
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lactobacillus johnsonii n6.2 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by University of Florida. Primary endpoints: Safety evaluated according to complete blood count (CBC) and complete comprehensive metabolic panel (CMP) at 52 weeks, Tolerance evaluated according to responses on weekly questionnaires at 52 weeks and 1 more. Started Feb 2020; status: completed.
02
Drugs
lactobacillus johnsonii n6.2
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03961347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961347.